# Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension

> **NCT00138944** · PHASE3 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 85 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** placebo
- **DRUG:** eplerenone

## Key facts

- **NCT ID:** NCT00138944
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-05
- **Final completion:** 2008-07
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2013-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138944, "Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00138944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*